Rapid in vivo measurement of β-amyloid reveals biphasic clearance kinetics in an Alzheimer’s mouse model

Carla M. Yuede,1 Hyo Lee,1 Jessica L. Restivo,1 Todd A. Davis,1 Jane C. Hettinger,1 Clare E. Wallace,1 Katherine L. Young,1 Margaret R. Hayne,1 Guojun Bu,2 Chen-zhong Li,3 and John R. Cirrito1

1Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110
2Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224
3Nanobioengineering/Bioelectronics Laboratory, Department of Biomedical Engineering, Florida International University, Miami, FL 33199

Findings from genetic, animal model, and human studies support the observation that accumulation of the β-amyloid (Aβ) peptide in the brain plays a central role in the pathogenic cascade of Alzheimer’s disease (AD). Human studies suggest that one key factor leading to accumulation is a defect in brain Aβ clearance. We have developed a novel microimmunoelectrode (MIE) to study the kinetics of Aβ clearance using an electrochemical approach. This is the first study using MIEs in vivo to measure rapid changes in Aβ levels in the brains of living mice. Extracellular, interstitial fluid (ISF) Aβ levels were measured in the hippocampus of APP/PS1 mice. Baseline levels of Aβ40 in the ISF are relatively stable and begin to decline within minutes of blocking Aβ production with a γ-secretase inhibitor. Pretreatment with a P-glycoprotein inhibitor, which blocks blood–brain barrier transport of Aβ, resulted in significant prolongation of Aβ40 half-life, but only in the latter phase of Aβ clearance from the ISF.

Accumulation of β-amyloid (Aβ) in the brain is an initiating factor in the pathological cascade leading to the development and progression of Alzheimer’s disease (AD; Musiek and Holtzman, 2015). High concentrations of Aβ promote its aggregation into toxic species, such as oligomers and fibrils, within the brain extracellular space. The balance between Aβ generation and elimination determines the concentration of Aβ in the brain interstitial fluid (ISF). Four broad pathways have been identified that eliminate Aβ from the brain: transport across the blood–brain barrier (BBB), proteolytic degradation, cellular uptake, and bulk flow clearance. Several of these pathways are impaired in individuals with AD (Preston et al., 2003; Nixon, 2007; van Assema et al., 2012). For instance, neprilysin and P-glycoprotein, an Aβ-degrading enzyme and an Aβ transporter at the BBB, respectively, are significantly reduced in human AD brain (Wang et al., 2005; Deo et al., 2014). In mouse models, deletion of either of these proteins increases brain Aβ levels, increases plaque load, and significantly prolongs the elimination rate of Aβ (or half-life) from the brain (Cirrito et al., 2005; Farris et al., 2007). Clearance of Aβ from the CSF is impaired in individuals with AD (Mawuenyega et al., 2010), strongly suggesting that a key factor leading to Aβ accumulation is a defect in eliminating the peptide from the brain. Aβ is secreted into the extracellular space, where it is soluble in the ISF under normal circumstances. The ISF pool of Aβ gives rise to pathological species, so mechanisms that regulate Aβ clearance from the ISF should impact AD pathogenesis. Aβ has a relatively short half-life compared with other proteins in the brain, indicating that some clearance mechanisms are fast-acting. Here, we use a novel microimmunoelectrode (MIE) to measure rapid changes in ISF Aβ metabolism in vivo.

Studying the temporal kinetics of Aβ within the brain ISF requires specialized techniques that specifically sample Aβ only from the ISF with the exclusion of peptide in other brain compartments (e.g., intracellular or membrane-bound) and can measure Aβ serially over time in a living mouse. In the past, we pioneered an in vivo microdialysis technique to measure ISF Aβ levels every 60 min over 3–5 d in mice (Cirrito et al., 2003, 2011). Although hourly sampling is still very useful, some studies require even faster temporal resolution. We recently developed an electrochemical technique using MIEs to detect Aβ (Prabhulkar et al., 2012) and have adapted it to measure ISF Aβ every 60 s over several hours in the brains of living mice.

RESULTS AND DISCUSSION

In vitro characterization of the MIE

Amperometry is an electrochemical technique used to measure oxidation of a wide range of molecules, most notably small molecules such as serotonin and dopamine in the brain (Wightman, 1988). Several national security biohazard de-
Aβ peptides in solution can be measured by exploiting the intrinsic electroactivity of Aβ (Vestergaard et al., 2005). The single tyrosine (Tyr) residue at position 10 of human Aβ bears a phenolic group that can be oxidized at an electrode surface. Oxidation releases electrons, which an electrode detects as current; the amount of current is directly proportional to the number of Tyr residues present on the concentration. Using square wave voltammetry (SWV), the voltage applied to a carbon fiber microelectrode is step-wise increased from 0 to 1.0 V. When the electrode scans through ~0.65 V, Tyr residues present in human Aβ oxidize, which is detected by the electrode as increased peak oxidation current. However, a 0.65-V potential will oxidize a variety of molecules, including all nearby Tyr within other proteins. We covalently attached anti-Aβ40 or anti-Aβ42 antibodies, mHJ2 and mHJ7.4, respectively, to the MIE surface to provide specificity for each target (Fig. 1 A). Albumin is then absorbed to the electrode surface to limit nonspecific signal. Tyr oxidation is irreversible, therefore, Aβ peptides oxidized at the electrode surface can only be measured once. Additionally, once the tyrosine amino acids within albumin and antibody are initially oxidized, they will not contribute signal to the MIE over time.

The Aβ MIE is a 5-μm-diam, 30–60-μm-long cylinder-shape similar to the carbon fiber microelectrodes used in other in vivo studies (Roitman et al., 2008). Murine Aβ lacks a Tyr at position 10, so in theory, should not produce an oxidative signal using the MIE. As expected, robust oxidative signal is detected with the MIE in a solution of human Aβ, whereas only negligible signal is observed in a concentration-matched solution of murine Aβ (Fig. 1 B). Post-hoc ELISAs were used to verify that the absolute concentration of murine and human Aβ were equal in these solutions. Importantly, the mHJ2 anti-Aβ40 antibody on the MIE binds to both mouse and human Aβ equally. Consequently, murine Aβ and wild-type mice serve as important negative controls to identify how specific the MIEs are at detecting only human Aβ as opposed to other electroactive molecules and proteins.

The antibody attached to the electrode is particularly important, as it provides specificity for the target and strongly influences MIE longevity. For the MIE to function, there must be excess antibody capable of binding fresh target; however, if all of the antibodies are bound to Aβ, the electrode becomes nonfunctional. MIEs are an application in which antibodies with a moderate affinity are ideal, so that the target has both an on-rate as well as a reasonable off-rate, allowing antibody binding capacity to remain open so new Aβ continues to bind. To prolong longevity of the MIE, we used an antibody specific for Aβ40 with moderate affinity (mHJ2 KD = 14 nM determined by surface plasmon resonance) to allow for dissociation.

For our initial in vitro studies, we attached a mouse monoclonal antibody specific for Aβ40 (mHJ2) and evaluated the electrode response in solutions of Aβ40 and Aβ42 using SWV. Oxidation peak height increased as concentration of Aβ40 increased (Fig. 2 A). At comparable concentrations in solution, the Aβ40 MIE is 52 times more selective for Aβ40 over Aβ42 (Fig. 2 B). Similarly, attaching mHJ7.4, an anti-Aβ42-specific antibody, we also saw an increase in peak height corresponding with increasing concentrations (Fig. 2 C). The Aβ42 MIE is 15,000 times more selective for Aβ42 than for Aβ40 (Fig. 2 D). The higher selectivity of the Aβ42 MIE is likely caused by the higher affinity of the antibody. This difference in selectivity is particularly important in vivo, where there are very low concentrations of Aβ42 compared with Aβ40. We have intentionally designed the MIEs to have widely different selectivity for Aβ40 and Aβ42 species to take into account practical considerations of electrode longevity and actual 40:42 ratios of the peptide in brain ISF. In the APP/PS1 mouse model used in these studies, the concentration of brain ISF Aβ42 is 10-fold lower than Aβ40. Consequently, the Aβ40 MIE actually has an effective 520-fold selectivity for Aβ40 versus Aβ42 in vivo.
In vivo MIEs to measure brain ISF Aβ

To measure rapid changes in brain ISF Aβ in the mouse hippocampus, we stereotaxically implanted Aβ40 MIEs into the hippocampus of anesthetized APP/PS1 and wild-type mice (Fig. 3 A). A large oxidation peak is observed at ∼0.65 V in APP/PS1 mice, whereas only a negligible oxidative signal is seen in scans of wild-type mice (Fig. 3 B). Variability in individual MIE length and sensitivity leads to variable oxidation peak heights for each electrode; therefore, each MIE must be calibrated against known concentrations of Aβ. The mean concentration of human Aβ40 in the ISF, as measured by the MIE, is 128.16 ng/ml. Within a single animal, the minute-to-minute variability of Aβ is 9.89 ± 1.88 ng/ml (mean ± SEM). These fluctuations appear to be biologically driven by rapid changes in Aβ production and clearance. In contrast, levels of murine Aβ in wild-type mice are essentially undetectable (Fig. 3 C). From these data, we infer that the MIE is at least 8,000-fold more selective in vivo for human Aβ as opposed to any other Tyr present in the brain ISF.

To evaluate stability of the MIE in vivo over time, we normalized the concentration of ISF Aβ at each time point to the mean baseline concentration from minute 10 to 25 for each mouse (Fig. 3 D). Concentrations are stable until minute 118, after which measurements have a small but significant decrease from baseline levels (P = 0.02). These results indicate that the MIE loses sensitivity after ∼2 h in vivo; therefore, measurements beyond 120 min need to be corrected for this decrease. The decrease in ISF Aβ after 2 h appears to be primarily a result of electrode sensitivity and possibly a small reduction in ISF Aβ levels caused by anesthesia. To verify using a complementary technique, we used in vivo microdialysis to measure ISF Aβ every hour before and during isoflurane anesthesia. ISF Aβ levels decrease by 14% during the first 3 h of isoflurane anesthesia; however, this was not a significant change in Aβ (n = 4, P = 0.135). For the following MIE studies, we only sampled Aβ for 100 min after implantation to avoid this confounding factor.

MIE technology

MIEs provide a powerful technology to assess the rapid dynamics of protein changes in brain within short periods. This provides a temporal resolution to measure proteins in vivo every 60 s, which was previously not feasible. One of the advantages, and disadvantages, of the Aβ MIE technique is that it only detects human Aβ species. Although wild-type mice serve as a negative control, this technique limits studies to those involving transgenic/knock-in mouse models that produce the human form of Aβ. The 5-µm-diam of the MIEs is smaller than most neuron cell bodies, so the electrodes create very little damage during insertion. Implantation of microelectrodes has been shown to activate microglia within 6 h, but not within the short timeframe of our study (Kozai et al., 2012). We examined tissue sections for evidence of lesions or microbleeds resulting from acute MIE implantation; in many cases tissue disruption caused by surgery was evident on the brain surface; however, the exact site of the MIE tip was very
small and normally undetectable by histology. Consequently, tissue damage is only a small concern using this technique.

MIEs only function for 2 h before starting to lose sensitivity. In contrast, our in vivo microdialysis technique samples Aβ every hour, but lasts for 3–5 d (Cirrito et al., 2003). The MIE and microdialysis approaches complement each other by enabling the study of both brief and prolonged events that regulate ISF Aβ metabolism. Measuring protein concentrations every 60 s enables us to study fast-acting mechanisms for Aβ production and clearance, which could not previously be studied. Specificity of the electrode depends on the antibody attached and the presence of an electroactive amino acid (such as tyrosine, tryptophan, or cysteine); therefore, it is possible that MIEs can be developed to detect other proteins as well.

Rapid measurement of Aβ half-life in vivo

P-glycoprotein (Pgp) removes brain ISF Aβ by transporting it across the BBB (Cirrito et al., 2005; Hartz et al., 2010). Pgp is expressed on the luminal surface of brain endothelial cells and transports the peptide out of those cells and into blood. Pgp-null mice (mdr1a/1b double knockout mice) have significantly impaired BBB transport of Aβ40; however, Aβ42 transport is minimally affected. Pgp-null mice crossed to Tg2576 APP transgenic mice also have significantly greater plaque load, and similarly, individuals with low Pgp expression have higher Aβ deposits in brain (Vogelgesang et al., 2002).

Using MIEs to measure real-time and rapid changes in ISF Aβ40, we evaluated clearance under normal conditions and after Pgp inhibition. Previous studies in rodents have shown XR9576 effectively blocks Pgp-mediated transport quickly, with maximum activity inhibited 30 min after injection, which then declines slowly due to low compound elimination (Bankstahl et al., 2008). We measured levels of XR9576 in brain tissue at 1 h after injection and found mean levels to be 533.0 ± 68.11 µM, where the IC50 for inhibition in vivo is 1.05 µM (Wanek et al., 2015). Therefore, we pretreated one group of APP/PS1 mice with XR9576 for 1 h before measuring Aβ40 clearance. Under anesthesia, we inserted an Aβ40 MIE into the hippocampus to measure baseline ISF Aβ40 levels for 15 min before administering Compound E, a γ-secretase inhibitor (GSI), to block Aβ generation. Inhibiting Pgp alone resulted in a 305% increase in baseline levels of Aβ40 compared with controls (Fig. 4 A). The increase in ISF Aβ detected with the MIE is much greater than previous studies using microdialysis (Cirrito et al., 2005). This is likely because of the difference of awake versus anesthetized mice and because the two techniques detect slightly different populations of ISF Aβ in vivo.

Treating mice with a GSI rapidly blocks Aβ generation, enabling us to assess the elimination of existing peptide present within the ISF. From these data, we can calculate an in vivo elimination half-life of endogenous Aβ. Although the absolute levels of Aβ40 were significantly higher in the XR9576-treated mice, ISF Aβ40 concentration still declined quickly after GSI treatment in both groups (Fig. 4 B). Compound E drug levels reach 395 nM brain tissue within 5 min after intraperitoneal injection (Fig. 4 C). This concentration is ∼1,200-fold higher than the IC50 of Compound E to block APP cleavage into Aβ (IC50 in CHO cells is 300 pM; Seiffert et al., 2000). Compound E levels in the brain decrease substantially by 60 min after injection; however, they still remain 30-fold higher than the IC50 (Fig. 4 C). Percent changes in ISF Aβ40 after GSI administration were transformed into log values to calculate rate of clearance over time (Fig. 4 D). We analyzed the overall rate of clearance in both groups from minutes 5–60, which was significantly
prolonged by 275% in the XR9576-treated mice compared with control mice (P = 0.012; Fig. 4 E). The overall pattern of changes observed in ISF Aβ after GSI administration and Pgp inhibition using the MIE are comparable to what we have previously reported (Cirrito et al., 2005).

Interestingly, however, the rates of clearance were not uniformly different throughout the entire course of the study; the semi-log plots of both groups actually show similar clearance rates up until 15 min, where they then begin to diverge (Fig. 4 D). Using a modified curve stripping analysis, we isolated two different slopes in the clearance profile. We found no significant differences in the clearance rate during the initial 15 min after GSI treatment (Fig. 4 F); however, the second phase in the clearance rate (minutes 16–60) was significantly slower in XR9576-treated mice (P = 0.001; Fig. 4 G). To determine if acute inhibition of Pgp influenced expression of low-density lipoprotein-1 (LRP1), or other genes related to APP processing or Aβ clearance, we examined mRNA levels in brain tissue 2 h after XR9756 treatment (see Materials and methods for specific genes). We did not find significant differences in mRNA expression levels in the brain, indicating the drug treatment is not affecting global expression of genes related to APP processing or Aβ elimination (n = 6/group; P = 0.08–0.94; cut off for multiple comparisons, P = 0.004). Similarly, LRP1 protein levels did not change in hippocampus after XR9576 administration (n = 9/group, P = 0.35). However, we did not assess expression in blood vessels specifically. Pgp does not appear to play a substantial role in brain Aβ clearance at high concentrations, but is a critical mechanism when Aβ levels decrease below a certain threshold.

Kinetics of Aβ clearance in vivo
Clearance of Aβ falls into four main categories: active BBB transport into the periphery, cellular uptake, proteolytic degradation, and passive bulk flow elimination. Both LRP1 and Pgp are expressed by endothelial cells (abluminally and luminally, respectively) and act cooperatively to transport Aβ from the perivascular space out of the brain into blood (Shi-
bata et al., 2000; Deane et al., 2004; Zlokovic et al., 2010). LRP1 and several family members have an additional role of cellular uptake of Aβ within the brain (Castellano et al., 2012; Kanekiyo et al., 2013). Proteases such as nephrilysin and matrix metalloproteinases (MMPs) degrade extracellular Aβ (Farris et al., 2007). Lastly, bulk flow mechanisms, including the glymphatic system, clear Aβ out of the ISF as part of the normal, passive fluid turnover (Xie et al., 2013).

By measuring ISF Aβ very rapidly, we were able to detect multiple rates of Aβ elimination from the brain. Our data using MIEs for rapid sampling determined that Aβ clearance does not follow first-order kinetics, as previously reported by our group using microdialysis (Cirrito et al., 2003). Instead, the rate of elimination varies with concentration. The initial rate of clearance, when ISF Aβ concentrations are high, has a very short half-life. However, as Aβ concentrations decline, the half-life is significantly longer. It is possible that the various Aβ clearance mechanisms contribute to different clearance rates. It will be necessary to explore these effects by blocking individual pathways and measuring rapid clearance to determine the role each mechanism plays in the immediate removal of Aβ from the ISF. Our data demonstrate that Pgp is critical for the slower elimination rate of Aβ at the BBB, which appears to account for an overall greater percentage of ISF Aβ clearance than the faster pathway. These results are similar to those reported by (Qosa et al., 2014) in that BBB clearance accounts for a greater percentage of Aβ clearance than proteolytic degradation, and Pgp inhibition slows this clearance pathway specifically.

Our data suggest that the speed and efficiency of Aβ clearance pathways may be different. A therapeutic strategy aimed at rapid clearance at only high concentrations may be different than a strategy that is designed for a sustained, possibly larger, suppression of Aβ. And if multiple pathways are targeted, then enhancing clearance mechanisms with different properties and rates could be beneficial.

**MATERIALS AND METHODS**

**Animals.** All experimental procedures involving animals were approved by the Animal Studies Committee at Washington University. We bred APP/PS1+−/− hemizygous mice (Jankowsky et al., 2004) to wild-type C3H/B6 mice (The Jackson Laboratory), and then used the APP/PS1+−/− offspring, or wild-type littermates, for experiments at 3 mo of age, before Aβ deposits are observed in this model. These mice contain a PS1Δβ mutation that was inserted into a single locus. Animals were screened for the PS1 and APP transgenes by polymerase chain reaction from tail DNA. Male and female littermate mice were distributed between experimental groups.

**MIE preparation.** MIEs were prepared following our previously described methods (Prabhulkar et al., 2012). Carbon fiber microelectrodes were used as the platform sensor because of their high signal-to-noise ratio, biological compatibility, and small size. Carbon-based electrodes have also been proven to sensitively detect Tyr oxidation (Vestergaard et al., 2005). In brief, a single length of carbon fiber (5-µm-diam; GoodFellow Corp.) was aspirated into a glass capillary tube (0.4-mm inner diameter, 4 inch length; A-M Systems), shaped using a pipette puller (Narishige PE-22), and attached to an insulated silver wire using conductive silver adhesive paste (Ted Pella, Inc.). The junction between the wire and the glass capillary tube was sealed using heat shrink tubing (NTE Electronics). The carbon fiber was cut using microsurgical scissors (World Precision Instruments, Inc.) to a length of 30–60 µm. To enhance binding of the capture antibody, the microelectrodes were pretreated using a triangular waveform from 0 to 3 V for 70 s in PBS, or in 150 mM NaCl solution (pH, 10) at 1.2 V for 4 min. The carboxylic groups on the carbon fiber surface were activated by application of 0.4 M of EDC and 0.1 M of NHSS solutions (Thermo Fisher Scientific) to form a semistable reactive amine NHS ester. The activated microelectrodes are placed in a solution of antibody (e.g., mHJ2 for Aβ40 or mHJ7.4 for Aβ42 and incubated at room temp for 10 min, and then 4°C overnight. After antibody attachment, MIEs were incubated with 0.05% ethanolamine to deactivate reactive amine sites and then 0.1% BSA to block nonspecific protein-binding sites.

In vitro MIE studies. In vitro calibration of the MIEs before experiments were conducted using a CH Instruments 660D Electrochemical Workstation with PicoAmp booster (CH Instruments Inc.). A conventional three-electrode cell consisting of an Ag/AgCl reference electrode (1 M KCl), and a platinum wire as a counter electrode was used in all experimental procedures. Synthetic human Aβ40, Aβ42, and mouse Aβ40 (American Peptide Co.) were prepared in fivefold serial dilutions ranging from 1 µg to 64 pg in 0.1% BSA in PBS. SWV was used to monitor the response of the electrode in different concentrations of Aβ. Actual concentration in each Aβ sample was determined by sandwich ELISA after each experiment. Aβ concentrations using the MIE were calculated based on standard curve values from the calibration ELISA. SWV parameters used were: Init E (V) = 0; Final E (V) = 1; Incr E (V) = 0.004; Amplitude (V) = 0.04; and Frequency (Hz) = 15.

In vivo MIE studies. To maintain consistency with our in vitro characterization of the Aβ40 MIE, we used a three electrode design in vivo as well. In addition to the MIE, a stainless steel bone screw used as a counter electrode, and an Ag/AgCl reference electrode (In Vivo Metrics) were implanted into the brain of preplaque (3–4 mo old) APP/PS1+−/− transgenic mice and wild-type littermates. All electrodes were stereotaxically implanted in to the brains of APP/PS1+−/− mice under isoflurane anesthesia. Mice were placed on a heating pad to maintain body temperature. For these experiments, Aβ40 MIEs were inserted into the hippocampus at coordinates: bregma –3.1 mm, 2.6 mm lateral to midline, and 1.7 mm below dura mater. Repetitive SWV scans were run every 60 s for
up to 180 min. The stereotax was enclosed in a faraday cage to reduce electrical noise. Electrodes were attached to a CH Instruments 830D Electrochemical Analyzer with PicoAmp booster. All electrodes were calibrated against known concentrations of Aβ40 before the experiment, and only MIEs showing increasing response to increasing concentrations of Aβ40 in vitro were used for in vivo experiments.

Aβ ELISA. ISF Aβ levels were assessed using sandwich ELISA as previously described (Cirrito et al., 2011). In brief, to assess Aβ40 and Aβ12 in MIE calibration solutions, mouse monoclonal antibodies (HJ2 or HJ7.4, respectively) were used to capture and a biotinylated central domain Aβ-specific antibody (HJ5.1) was used to detect, followed by streptavidin-poly-HRP-20 (Fitzgerald Industries). All ELISA assays were developed using Super Slow ELISA TMB (Sigma-Aldrich) and absorbance read on an Epoch plate reader (Bio-Tek) at 650 nm.

Aβ elimination half-life. ISF Aβ half-life was determined similar to our previously described method using microdialysis (Cirrito et al., 2003). MIEs were inserted into the hippocampus and SWV scans were run until the baseline became stable (10–20 min). After baseline stabilization, mice were administered a potent, blood–brain permeable γ-secretase inhibitor, Compound E (synthesized by AsisChem; 30 mg/kg) intraperitoneally to rapidly block Aβ production. ISF Aβ levels were measured by SWV scans every 60 s for 60–90 min. The half-life of ISF Aβ was calculated on the basis of the slope of the semilog plot of percent change in Aβ versus time. Only Aβ values that were continually decreasing were included in half-life analysis (within the 60 min after Compound E administration).

Quantitative real-time PCR (qRT-PCR). 3-mo-old mice were treated with XR9576 (80 mg/kg i.v.) or vehicle (equal volume 5% dextrose). Mice were sacrificed 2 h later, and their brains were microdissected and frozen on dry ice. Total RNA were extracted using the RNeasy Mini kit (QIAGEN) and reverse transcribed using the High Capacity cDNA Reverse Transcription kit (Invitrogen). The APP processing-related genes evaluated were as follows: Amyloid precursor protein (APP), Presenilin 1 and 2 (PSEN1 and PSEN2), Nicasta, Anterior pharynx-defective 1 (APH–1), β-secretase 1 (BACE1), A Disintegrin and metalloproteinase domain-containing protein 10 and 17 (ADAM10 and ADAM17). The Aβ clearance-related genes evaluated were as follows: P-glycoprotein (Pgp), low density lipoprotein 1 (LRP1), insulin degrading enzyme (IDE), Neprilysin (NEP), and matrix metalloproteinase 2 and 9 (MMP2 and MMP9). Individual primers were designed using Harvard Medical School Primer Bank. qRT-PCR was performed using the Fast SYBR Green Master Mix (Applied Biosystems) in ABI 7900HT (Applied Biosystems) with the default thermal cycling program. Dissociation curves were analyzed after qPCR assay to confirm primer efficacy. Relative mRNA levels were calculated using the ΔΔCt method, normalizing cDNA levels to endogenous mouse GAPDH. Student’s t tests with p-value correction for multiple comparisons were used to analyze changes in gene expression using the GraphPad Prism 6 software.

LRP1 protein levels in brain tissue. Hippocampi from control and XR9576-treated mice were lysed in buffer containing 150 mM NaCl, 50 mM Tris, 0.5% deoxycholic acid, 1% Triton X-100, 0.1% SDS, 2.5 mM EDTA, and broad spectrum protease inhibitors. Protein concentration was determined in each sample using a Micro BCA Protein Assay kit (Thermo Fisher Scientific). 15 µg of protein for each sample was used for SDS-PAGE using 4–12% Bis–Tris gels with MES running buffer (Life Technologies). Rabbit polyclonal anti-LRP1 antibody was produced in G. Bu’s laboratory (Mayo Clinic, Jacksonville, FL), followed by goat anti–rabbit HRP (Santa Cruz Biotechnology). As a loading control, blots were stripped and reprobed with mouse anti–GAPDH (Sigma–Aldrich) and sheep anti–mouse peroxidase (GE Life Sciences). Blots were imaged on a ImageStation 440CF (Kodak) and bands quantified using 1D image analysis software (Kodak). LRP1 bands were normalized to GAPDH bands, and then for each gel the control-treated and XR9576-treated tissues were normalized to the mean of control bands intensity. LRP1 protein levels were compared between groups by unpaired Student’s t test.

Compound E and XR9576 levels in brain tissue. Samples were extracted with indicated volume of 45% methanol/45% acetonitrile/8% water/2% formic acid containing 1 µM LY411575 as internal standard so that each hemisphere was extracted at a concentration of 200 µg/ml. After lysis by shaking for 5 min at 20 Hz in the TissueLyserII (QIAGEN) with a 4-mm stainless steel ball, samples were centrifuged and then filtered through a 0.8-µm PES spin filter (Sartorius). Filtered samples were diluted 1:20 with LC-MS grade water and centrifuged to remove any particulates. Samples were analyzed on a Q-Exact Mass Spectrometer (Thermo Fisher Scientific) operated in positive profile mode at a resolution setting of 70,000 with a scan range of m/z 100–500. Spectra were internally calibrated using the lock mass feature against ever present airborne contaminants. The system was equipped with a 1200 Capillary LC (Agilent) and a 0.5 × 100 mm 3 µm PLRPS column (Higgins Analytical). Solvents were 100% water (A) and acetonitrile (B) with 0.1% formic acid. The chromatographic gradient was as follows: 0% B from 0–4 min followed by a linear ramp up to 100% B over 6 min, a hold at 100% B for 3 min, a 2-min ramp back down to 0% B, and, finally, a reequilibration time of 15 min. 1 µl of sample was injected such that 50 fmol of internal standard was loaded on column each time for data normalization. Data were analyzed using the QuantBrowser application of Xcalibur (Thermo Fisher Scientific). Compound E and XR9576 concentrations in mouse brain were calculated based on comparing normalized area counts with an external calibration curve prepared in control mouse brain extract.
Statistical analysis. All in vitro measurements were performed in triplicate and the mean of the three SWV scans was used for analysis. All current responses recorded were subtracted from background and fit to baseline for peak analysis using CH Instruments software. Results are expressed as mean ± SE. Differences in clearance rates between groups were analyzed in GraphPad Prism software using T-tests; repeated measures ANOVA with Bonferroni post-hoc tests was used to analyze percent changes in baseline levels over time. Statistical significance in all analyses was set at P < 0.05.

ACKNOWLEDGMENTS

We would like to thank Dr. Mitch Roitman and his laboratory for valuable discussions and advice regarding the in vivo electrochemical studies, and the Proteomics and Mass Spectrometry Facility at the Danforth Plant Science Center for the measurement of Compound E and XR9576 levels.

This work was supported by National Institutes of Health grants R21 AG045691 (J.R. Cirrito and C.M. Yuede), R01 AG042513 (J.R. Cirrito), R01 NS074983 (J.R. Cirrito), P01 AG045691 (J.R. Cirrito) and the Brightfocus Foundation (J.R. Cirrito).

The authors declare no competing financial interests.

Submitted: 3 September 2015
Accepted: 4 March 2016

REFERENCES

Bunkastall, J.P., C. Kuintner, A. Abraham, R. Karch, J. Stanek, T. Wanek, W. Wadas, K. Kletter, M. Müller, W. Löser, and O. Langer. 2008. Tartrazin-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-14C-verapamil and PET. J. Nucl. Med. 49:1328–1335. http://dx.doi.org/10.2967/jnumed.108.051235

Castellano, J.M., R. Deane, A.J. Gottesdiener, P.B. Verghese, F.R. Stewart, T. West, A.C. Paletti, T.R. Kasper, R.B. DeMattos, B.V. Zlokovic, and R.M. Carelli. 2008. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: kinetic analysis and mechanistic understanding. J. Neurosci. 23:8844–8853.

Cirrito, J.R., R. Deane, A.M. Fagan, M.L. Spinner, M. Pasadanian, M.B. Finn, H. Jiang, J.L. Prior, A. Sagare, K.R. Bales, et al. 2005. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115:3265–3290. http://dx.doi.org/10.1172/JCI25247

Cirrito, J.R., B.M. Disabato, J.L. Restivo, D.K. Verges, W.D. Goebel, A. Sathyam, D. Hayreh, G. D’Angelo, T. Benzinger, H. Yoon, et al. 2011. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc. Natl. Acad. Sci. USA. 108:14968–14973. http://dx.doi.org/10.1073/pnas.1107411108

Deane, R., Z. Wu, A. Sagare, J. Davis, S. Du Yan, K. Hamm, F. Xu, M. Parisi, B. LaRue, H.W. Hu, et al. 2004. LRP amyloid-β peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 43:333–344. http://dx.doi.org/10.1016/j.neuron.2004.07.017

Deo, A.K., S. Borson, J.M. Link, K. Domino, J.F. Eary, B. Ke, T.L. Richards, D.A. Mankoff, S. Minoshima, F. O’Sullivan, et al. 2014. Activity of p-glycoprotein, a β-amyloid transporter at the blood-brain barrier, is compromised in patients with mild Alzheimer disease. J. Nucl. Med. 55:1106–1111. http://dx.doi.org/10.2967/jnumed.113.130161

Farris, W., S.G. Schütz, J.R., Cirrito, G.M. Shankar, X. Sun, A. George, M.A. Lessring, D.M. Walsh, W.Q. Qu, D.M. Holtzman, and D.J. Selkoe. 2007. Loss of nephilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am. J. Pathol. 171:241–251. http://dx.doi.org/10.2353/apth.2007.070708

Hartz, A.M., D.S. Miller, and B. Bauer. 2010. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer’s disease. Mol. Pharmacol. 77:715–723. http://dx.doi.org/10.1124/mol.109.061754

Jankowsky, J.L., D.J. Fadale, J. Anderson, G.M. Xu, V. Gonzales, N.A. Jenkins, N.G. Copeland, M.K. Lee, L.H. Younkin, S.L. Wagner, et al. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13:159–170. http://dx.doi.org/10.1093/hmg/ddh019

Kaneyko, T., J.R. Cirrito, C.C. Liu, M. Shinohara, J. Li, D.R. Shuler, M. Shinohara, D.M. Holtzman, and G. Bu. 2013. Neuronal clearance of amyloid-β by endocytic receptor LR1P1. J. Neurosci. 33:19276–19283. http://dx.doi.org/10.1523/JNEUROSCI.3487-13.2013

Kozai, T.D.Y., A.L. Vazquez, C.L. Weaver, S.G. Kim, and X.T. Cui. 2012. In vivo two-photon microscopy reveals immediate microglial reaction to implantation of microelectrode through extension of processes. J. Neurog. 9:066001. http://dx.doi.org/10.1088/1741-2560/9/6/066001

Mawusyega, K.G., W. Sigurdson, V. Ovod, L. Munsell, T. Kasten, J.C. Morris, K.E. Yarasheski, and R.J. Bateman. 2010. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 330:1774. http://dx.doi.org/10.1126/science.1197623

Musiek, E.S., and D.M. Holtzman. 2015. Three dimensions of the amyloid hypothesis: time, space and ‘wringmen’. Nat. Neurosci. 18:800–806. http://dx.doi.org/10.1038/nn.4018

Nixon, R.A. 2007. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell. Sci. 120:4081–4091. http://dx.doi.org/10.1242/jcs.019265

Prabhulkar, S., R. Pratyszek, J.R. Cirrito, Z.Z. Wu, and C.Z. Li. 2012. Microbensorbosis for Alzheimer’s disease diagnostics: detection of amyloid beta biomarkers. J. Neurochem. 122:374–381. http://dx.doi.org/10.1111/j.1471-4159.2012.07709.x

Preston, S.D., P.V. Stewart, A. Wilkinson, J.A.R. Nicoll, and R. O. Weller. 2003. Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid β from the human brain. Neuropathol. Appl. Neurobiol. 29:106–117. http://dx.doi.org/10.1046/j.1465-6999.2003.00424.x

Qosa, H., B.S. Abuasal, I.A. Romero, B. Weksler, P.-O. Couraud, J.N. Keller, and A. Kaddoumi. 2014. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropsychopharmacology. 79:668–678. http://dx.doi.org/10.1016/j.neuropsychopharmacology.2014.01.023

Roitman, M.F., R.A. Wheeler, R.M. Wightman, and R.M. Carelli. 2008. Real-time chemical responses in the nucleus accumbens differentiate rewarding and aversive stimuli. Nat. Neurosci. 11:1376–1377. http://dx.doi.org/10.1038/nn.2219

Sadik, O.A., W.H. Land, and J. Wang. 2003. Targeting chemical and biological warfare agents at the molecular level. Electroanalysis. 15:1149–1159. http://dx.doi.org/10.1002/elan.200390140

Seifert, D., J.D. Bradley, C.M. Rominger, D.H. Rominger, F. Yang, J.E. Meredith Jr., Q. Wang, A.H. Roach, L.A. Thompson, S.M. Spitz, et al. 2000. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J. Biol. Chem. 275:34086–34091. http://dx.doi.org/10.1074/jbc.M00430200

Shibata, M., S. Yamaoda, S.R. Kumar, M. Calero, J. Bading, B. Fring Morme, D.M. Holtzman, C.A. Miller, D.K. Strickland, J. Gluso, and B.V. Zlokovic. 2000. Clearance of Alzheimer’s amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:1489–1499. http://dx.doi.org/10.1172/JCI10498
van Assena, D.M., M. Lubberink, M. Bauer, W.M. van der Flier, R.C. Schuit, A.D. Windhorst, E.F.I. Comans, N.J. Hoetjes, N. Tolboom, O. Langer, et al. 2012. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain. 135:181–189. http://dx.doi.org/10.1093/brain/awr298

Vestergaard, M., K. Kerman, M. Saito, N. Nagatani, Y. Takamura, and E. Tamiya. 2005. A rapid label-free electrochemical detection and kinetic study of Alzheimer's amyloid beta aggregation. J. Am. Chem. Soc. 127:11892–11893. http://dx.doi.org/10.1021/ja052522q

Vogelgesang, S., I. Cascorbi, E. Schroeder, J. Pahnke, H.K. Kroemer, W. Siegmund, C. Kunert-Keil, L.C. Walker, and R.W. Warzok. 2002. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 12:535–541. http://dx.doi.org/10.1097/00008571-200210000-00005

Wanek, T., K. Römermann, S. Mairinger, J. Stanek, M. Sauberer, T. Filip, A. Traxl, C. Kuntner, J. Pahnke, F. Bauer, et al. 2015. Factors governing P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier measured with positron emission tomography. Mol. Pharm. 12:3214–3225. http://dx.doi.org/10.1021/acs.molpharmaceut.5b00168

Wang, D.S., R.B. Lipton, M.J. Katz, P. Davies, H. Buschke, G. Kuslansky, J. Verghese, S.G. Younkin, C. Eckman, and D.W. Dickson. 2005. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J. Neuropathol. Exp. Neurol. 64:378–385. http://dx.doi.org/10.1093/jnen/64.5.378

Wightman, R.M. 1988. Voltammetry with microscopic electrodes in new domains. Science. 240:415–420. http://dx.doi.org/10.1126/science.240.4851.415

Xie, L., H. Kang, Q. Xu, M.J. Chen, Y. Liao, M. Thiyagarajan, J. O'Donnell, D.J. Christensen, C. Nicholson, J.J. Iliff, et al. 2013. Sleep drives metabolite clearance from the adult brain. Science. 342:373–377. http://dx.doi.org/10.1126/science.1241224

Zlokovic, B.V., R. Deane, A.P. Sagare, R.D. Bell, and E.A. Winkler. 2010. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain. J. Neurochem. 115:1077–1089. http://dx.doi.org/10.1111/j.1471-4159.2010.07002.x